Saturday 17 October 2026 Export ORGO’s income statement to Excel — free account

Organogenesis

ORGO Healthcare Drug Manufacturers Specialty & Generic

Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 56.7%, EPS fell 670.0%, free cash flow grew 10.3% and total debt rose 10,940.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.99 0.12 −10.81%

Follow ORGO

Alert me

Market cap: $142.8M
P/E: 0.0×
Fwd P/E: −2.6×
Dividend yield: —
F-score: 4/9
Altman Z: 3.03
Beneish M: −1.41
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.04

Total sells 2.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	2	—	—	—	—	—	—	—
Sell	1	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 44.67%

Capital & Financial Ratios $m

Market Cap 142.83

Revenue 457.45

Net Income (84.16)

Free Cash Flow 20.84

Net Debt (36.02)

Current Ratio 3.52

Debt/Equity 0.07

P/E ratio 0.00

Fwd P/E (2.59)

P/S ratio 0.28

P/B ratio 0.86

Past 5Y EPS Growth (1.28%)

This Y EPS Growth (575.08%)

Next Y EPS Growth 77.45%

Next Y revenue growth (65.24%)

Next 5Y EPS Growth 9.50%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.05%

10-year low 10-year high

P/B against its own 10 years 0.05%

10-year low 10-year high

EV/Sales against its own 10 years 0.05%

10-year low 10-year high

EV/FCF against its own 10 years 0.11%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	104	136	94	47
Receivables	82	110	217	101
Inventory	28	26	30	29
Other	—	—	2	4
	225	286	362	200

	2023	2024	2025	Q'26
Payables	31	29	32	29
ST’ Debt	5	—	—	—
Other	—	—	—	—
	81	77	100	57

Compound Annual Growth %

	10y	5y	3y
Sales	—	10.77%	7.76%
Cash Flow	—	0.00%	0.00%
Earnings	—	3.04%	8.83%
Book Value	—	16.18%	4.15%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	37	44	—	—	—
’25	87	101	151	226	564
’24	110	130	115	127	482
’23	108	117	109	100	433
’22	97	121	117	116	451
’21	103	123	114	128	467
’20	62	69	101	107	338

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	21	(32)	—	—	—
’25	(20)	(33)	3	39	(10)
’24	(10)	5	9	11	14
’23	(5)	9	17	11	31
’22	1	10	5	8	25
’21	(1)	17	28	18	62
’20	(17)	(9)	9	23	5

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	18	(33)	—	—	—
’25	(24)	(37)	1	35	(24)
’24	(12)	3	6	8	4
’23	(13)	1	11	7	7
’22	(5)	4	(5)	(3)	(9)
’21	(6)	13	11	13	31
’20	(22)	(12)	3	18	(12)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.44)	(0.77)	—	—	—
’25	(0.17)	(0.10)	0.11	0.24	0.15
’24	(0.02)	(0.13)	0.09	0.04	(0.01)
’23	(0.02)	0.04	0.02	0.00	0.04
’22	(0.01)	0.07	0.00	0.06	0.12
’21	0.07	0.15	0.09	0.39	0.71
’20	(0.16)	(0.05)	0.19	0.15	0.16

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	9.28	9.47	3.56	2.47	7.13	2.23	1.80	2.17	2.61	Analyst estimates 2026–2028 Powerpack
	High	—	10.18	10.87	310.90	7.61	24.34	9.67	4.50	4.71	7.08
People
People	Employees	—	—	700	835	910	950	1,030	862	869	854
	Revenue/emp, $m	0.00	0.00	0.28	0.31	0.37	0.49	0.44	0.50	0.55	0.66
Income, $m
Income, $m	Revenue	139	199	193	261	338	467	451	433	482	564
	Gross margin, %	65.26	69.16	64.43	70.90	74.19	75.57	76.71	75.42	75.99	75.62
	EBT	(15)	(15)	(65)	(39)	18	63	20	10	(3)	47
	EBT margin, %	(10.60)	(7.33)	(33.47)	(14.77)	5.25	13.50	4.50	2.40	(0.58)	8.33
	Net income	(15)	(8)	(65)	(39)	17	94	16	5	1	37
	Depreciation	7	6	7	10	8	17	18	23	25	27
Per share, $
Per share, $	Revenue	2.20	3.11	2.79	2.81	3.14	3.64	3.47	3.30	3.66	4.45
	Earnings	(0.23)	(0.12)	(0.71)	(0.44)	0.17	0.74	0.12	0.04	(0.01)	0.16
	Cash flow	(0.08)	(0.05)	(0.87)	(0.36)	0.05	0.48	0.19	0.24	0.11	(0.08)
	Capex	(0.02)	(0.04)	(0.03)	(0.07)	(0.16)	(0.24)	(0.26)	(0.19)	(0.08)	(0.11)
	Free cash flow	(0.10)	(0.09)	(0.90)	(0.43)	(0.11)	0.24	(0.07)	0.05	0.03	(0.19)
	Book value	0.00	(0.13)	0.68	0.60	1.32	1.88	2.04	2.12	2.00	2.37
	Shares, m	63	64	69	93	108	128	130	131	132	127
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	50.20	12.49	20.96	114.29	0.00	57.56
	P/S	0.00	0.00	0.00	1.71	2.40	2.54	0.75	1.24	0.87	1.16
	P/B	0.00	0.00	15.00	8.03	5.72	4.91	1.28	1.92	1.60	2.19
	EV/Sales	0.00	0.00	0.00	1.87	2.40	2.45	0.68	1.15	0.61	1.03
	EV/FCF	0.00	0.00	(10.77)	(12.32)	(66.43)	37.22	(33.96)	76.18	69.90	(23.75)
Cash, $m
Cash, $m	Operating cash flow	(5)	(3)	(61)	(34)	5	62	25	31	14	(10)
	Capex	(1)	(2)	(2)	(6)	(18)	(31)	(34)	(24)	(10)	(14)
	Free cash flow	(6)	(6)	(62)	(40)	(12)	31	(9)	7	4	(24)
Balance, $m
Balance, $m	Working capital	1	(2)	15	66	106	144	148	145	208	262
	Total debt	—	101	71	101	85	73	71	68	1	13
	Net debt	(1)	99	50	40	0	(41)	(33)	(36)	(135)	(82)
	Shareholders’ equity	—	(9)	47	56	142	241	266	279	263	300
Returns, %
Returns, %	ROA	(10.86)	(11.85)	(41.51)	(20.44)	6.75	25.69	3.48	1.09	(0.20)	3.65
	ROIC	0.00	(3.79)	(33.25)	(19.47)	11.77	22.54	5.98	3.23	(0.63)	12.78
	ROE	(339.74)	170.81	(408.72)	(76.55)	17.46	49.17	6.13	1.82	(0.35)	7.11

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AKBA Akebia Therapeutics, Inc.	$192.7M	— (loss-making)	— (loss-making)	−21.36% (below 0%: shrinking)	n/m	−88.99% (below 0%: shrinking)	78.78%	(12.88%)	Compare
DERM Journey Medical Corporation	$144.7M	— (loss-making)	91.8×	+23.33% (above 0%: growing)	n/m	−84.08% (below 0%: shrinking)	66.81%	2.46%	Compare
ORGO Organogenesis	$142.8M	— (loss-making)	— (loss-making)	−56.68% (below 0%: shrinking)	n/m	+10.29% (above 0%: growing)	45.90%	(116.54%)
CRDL Cardiol Therapeutics Inc.	$138.8M	— (loss-making)	— (loss-making)	—	n/m	+10.61% (above 0%: growing)	0.00%	0.00%	Compare
OGI Organigram Global Inc.	$131.4M	2.0×	11.4×	+49.28% (above 0%: growing)	n/m	−192.32% (below 0%: shrinking)	39.16%	5.04%	Compare
BGM BGM Group Ltd.	$114.7M	144×	44.9×	−2.59% (below 0%: shrinking)	−85.71% (below 0%: shrinking)	+3.00% (above 0%: growing)	7.12%	0.00%	Compare
PROCF Sofgen Pharma S.A	$114.0M	0.1×	4.0×	+17.28% (above 0%: growing)	n/m	+231.11% (above 0%: growing)	56.09%	36.48%	Compare
CPIX Cumberland Pharmaceuticals Inc.	$113.0M	— (loss-making)	— (loss-making)	−56.28% (below 0%: shrinking)	n/m	−82.78% (below 0%: shrinking)	100.00%	(1,898.20%)	Compare
CLVR Clever Leaves Holdings Inc.	$96.5M	— (loss-making)	— (loss-making)	+5.36% (above 0%: growing)	n/m	+70.31% (above 0%: growing)	(7.46%)	(105.91%)	Compare
Median of peers	$123.0M	2.0×	28.2×	+5.36%	—	−39.89%	47.62%	0.00%

All 86 Drug Manufacturers Specialty & Generic stocks →

Organogenesis (ORGO) key facts

Strength: Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024.
Organogenesis (ORGO) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ORGO traded at $0.99, a market capitalization of $142.8 million.
Return on equity was 7.11% and debt-to-equity 0.07.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 3.03 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.